MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 (Ibudilast) For Chlorine-induced Acute Respiratory Distress Syndrome, Once Issued, This Patent Is Expected To Expire No Earlier Than January 2042
Portfolio Pulse from Benzinga Newsdesk
MediciNova has received a notice of allowance for a new patent covering MN-166 (Ibudilast) for the treatment of chlorine-induced acute respiratory distress syndrome. This patent, once issued, is expected to expire no earlier than January 2042, potentially extending the commercial exclusivity of MN-166.

May 14, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The notice of allowance for a new patent on MN-166 (Ibudilast) for chlorine-induced acute respiratory distress syndrome extends MediciNova's commercial exclusivity, potentially enhancing its long-term revenue prospects.
The issuance of a new patent for MN-166 (Ibudilast) for a specific treatment not only secures MediciNova's intellectual property but also potentially extends its market exclusivity, which can lead to sustained revenue from this product. This development is likely to be viewed positively by investors, as it enhances the company's asset value and future earnings potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100